All Photos(1)

Documents

1457301

USP

Naproxen

Name: Naproxen
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Linear Formula:

CH₃OC₁₀H₆CH(CH₃)CO₂H

CAS Number:

22204-53-1

Molecular Weight:

230.26

Beilstein:

3591068

MDL number:

MFCD00010500

UNSPSC Code:

41116107

PubChem Substance ID:

329750529

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

naproxen

manufacturer/tradename

USP

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

152-154 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O

InChI

1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1

InChI key

CMWTZPSULFXXJA-VIFPVBQESA-N

Gene Information

human ... PTGS1(5742) , PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Chromatography Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Naproxen USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Dexamethasone Compounded Oral Suspension
Naproxen
Naproxen Compounded Oral Suspension
Naproxen Delayed-Release Tablets
Naproxen Oral Suspension
Naproxen Tablets
Terazosin Tablets

Biochem/physiol Actions

Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1457312

1457425

08129

6-Methoxy-2-naphthol, pharmaceutical impurity standard

79584

2-Ethyl-6-methoxynaphthalene, pharmaceutical impurity standard

80713

(1RS)-1-(6-Methoxynaphthalen-2-yl)ethanol, pharmaceutical impurity standard

82170

(R)-Naproxen, pharmaceutical impurity standard

07506

(S)-Naproxen ethyl ester, pharmaceutical impurity standard

80822

(S)-Naproxen methyl ester, pharmaceutical impurity standard

80816

(2S)-2-(5-Chloro-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

80821

(2S)-2-(5-Iodo-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

80818

(2S)-2-(5-Bromo-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

07503

2-Bromo-6-methoxynaphthalene, pharmaceutical impurity standard

07499

2-Methoxynaphthalene, pharmaceutical impurity standard

07547

6-Methoxy-2-naphthoic acid, pharmaceutical impurity standard

BP435

Naproxen, British Pharmacopoeia (BP) Reference Standard

1457436

PHR2254

Naproxen 1,2,3 Propanetriol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2256

Naproxen 1,3-Butylene Glycol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2219

Naproxen 1,2 Propylene Glycol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2248

Naproxen 2,3-Butylene Glycol Ester, pharmaceutical secondary standard

PHR2257

Naproxen Isopropyl Ester, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2524

Naproxen Impurity N, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2525

Naproxen Impurity M, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2527

PHR2526

Naproxen Impurity H, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2520

Naproxen Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2519

Naproxen Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2518

PHR2523

PHR2530

rac-Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2517

PHR2521

Naproxen Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2522

Naproxen Impurity I, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2528

Naproxen Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2529

Naproxen Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

GHS08,GHS07,GHS09

Signal Word

Warning

Hazard Statements

H302,H315,H319,H335,H361fd,H411

Precautionary Statements

P202 - P273 - P301 + P312 - P302 + P352 - P305 + P351 + P338 - P308 + P313

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.

Marta L Capone et al.

Journal of the American College of Cardiology, 45(8), 1295-1301 (2005-04-20)

We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen. The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin in patients with arthritis and cardiovascular disease. The incubation of washed platelets with naproxen for 5

Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults.

Christopher Derry et al.

The Cochrane database of systematic reviews, (1)(1), CD004234-CD004234 (2009-01-23)

Naproxen, a non-steroidal anti-inflammatory drug, is used to treat various painful conditions including postoperative pain, and is often administered as the sodium salt to improve its solubility. This review updates a 2004 Cochrane review showing that naproxen sodium 550 mg

Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine.

Chuthamanee C Suthisisang et al.

Headache, 50(5), 808-818 (2010-03-20)

To assess the efficacy and safety of naproxen sodium in the treatment of acute migraine attacks. Non-steroidal anti-inflammatory drugs including naproxen sodium have been used in treating migraine attack. A number of clinical trials of naproxen sodium in migraine have

Renal papillary necrosis induced by naproxen.

Larisa Kovacevic et al.

Pediatric nephrology (Berlin, Germany), 18(8), 826-829 (2003-05-30)

A 17-year-old healthy girl was admitted to our hospital with diffuse abdominal pain and decreased oral intake of about 11 days duration. About a week prior to admission, she had taken naproxen, 250 mg four times a day for 4

Controlled release of liposome-encapsulated Naproxen from core-sheath electrospun nanofibers.

Zhuang Li et al.

Carbohydrate polymers, 111, 18-24 (2014-07-20)

Naproxen (NAP) loaded nanofibers of different structures have been successfully prepared by electrospinning. The structures of the nanofibers are NAP and cellulose acetate (CA) mixed nanofibers (NF-1), nanofibers with NAP/CA mixed core and CA sheath (NF-2), and NAP loaded liposomes

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service